Letter to the Editor| Volume 78, P157-158, August 2020

The Impact Of Diabetes Mellitus And Microvascular Complications On Heart Failure Biomarkers

Published:April 15, 2020DOI:


      • HF-biomarkers used in the general population are also suitable in patients with DM
      • sST2 levels are significantly correlated with NT-proBNP and hypocholesterolemia
      • Gal-3 sees the highest levels in subjects with DM and microvascular complications
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Shah A.D.
        • Langenberg C.
        • Rapsomaniki E.
        • Denaxas S.
        • Pujades-Rodriguez M.
        • Gale C.P.
        • et al.
        Type 2 Diabetes And Incidence Of Cardiovascular Diseases: A Cohort Study In 1•9 Million People.
        Lancet Diabetes Endocrinol. 2015; 3: 105-113
        • Chow S.L.
        • Maisel A.S.
        • Anand I.
        • Bozkurt B.
        • de Boer R.A.
        • Felker G.M.
        • et al.
        Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association.
        Circulation. 2017; 135: e1054-e1091
        • Sandesara P.B.
        • O'Neal W.T.
        • Kelli H.M.
        • Samman-Tahhan A.
        • Hammadah M.
        • Quyyumi A.A.
        • Sperling L.S.
        The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction.
        Diabetes Care. 2018; 41: 150-155
        • Kozakova M.
        • Palombo C.
        Diabetes Mellitus, Arterial Wall, and Cardiovascular Risk Assessment.
        Int J Environ Res Public Health. 2016; 13: 201
        • Domanski M.
        • Krause-Steinrauf H.
        • Deedwania P.
        • Follmann D.
        • Ghali J.K.
        • Gilbert E.
        • et al.
        The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial.
        J Am Coll Cardiol. 2003; 42: 914-922
        • Macdonald M.R.
        • Petrie M.C.
        • Varyani F.
        • Östergren J.
        • Michelson E.L.
        • Young J.B.
        • et al.
        Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
        Eur Heart J. 2008; 29: 1377-1385
        • Ohkuma T.
        • Jun M.
        • Woodward M.
        • Zoungas S.
        • Cooper M.E.
        • Grobbee D.E.
        • et al.
        Cardiac stress and inflammatory markers as predictors of heart failure in patients with type 2 diabetes: the ADVANCE trial.
        Diabetes Care. 2017; 40: 1203-1209
        • Sitar Taut A.V.
        • Pop D.
        • Zdrenghea D.T.
        NT-proBNP values in elderly heart failure patients with atrial fibrillation and diabetes.
        J Diabetes Complications. 2015; 29: 1119-1123
        • Atalar M.N.
        • Abuşoğlu S.
        • Ünlü A.
        • Tok O.
        • İpekçi S.H.
        • Baldane S.
        • Kebapcilar L.
        Assessment of serum galectin-3, methylated arginine and Hs-CRP levels in type 2 diabetes and prediabetes.
        Life Sci. 2019; 231116577
        • Lin Y.H.
        • Zhang R.C.
        • Hou L.B.
        • Wang K.J.
        • Ye Z.N.
        • Huang T.
        • et al.
        Distribution and clinical association of plasma soluble ST2 during the development of type 2 diabetes.
        Diabetes Res Clin Pract. 2016; 118: 140-145